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ABSTRACT 
Objective: To compare the efficacies of neurological 
physical examination, neurothesiometer and 
PainDETECT questionnaire in diagnosing diabetic 
neuropathy. 
Study Design: Prospective cross-sectional 
Place and Duration of Study: Department of General 
Medicine, Nishtar Hospital Multan, Pakistan from 1st 
December 2018 to 10th March 2019. 
Materials and Methods: One hundred and four 
patients of both type 1 and type 2 diabetes visiting the 
outdoor department were included in this study. They 
were assessed by lab results of glycosylated 
hemoglobin, fasting and random blood sugar levels and 
neurological physical examination. 
Results: The physical examination with Michigan 
Neuropathy Screening instrument showed that around 
29 of the patients were having established neuropathy. 
The PainDETECT questionnaire on the other hand 
showed about 42 patients having a definitive 
neuropathy while the neurothesiometer showed that 79 
of the total patients had varying degrees of neuropathy. 
Conclusion: The neurothesiometer is a better 
diagnostic tool for diagnosing diabetic neuropathy in 
patients. 
Introduction 
Diabetic neuropathy is a very common condition 
prevalent is Diabetics. Neuropathy is present in most 
of the patients affected by diabetes and is major cause 
of their morbidity. (1) The pathogenesis of diabetic 
neuropathy has been attributed to the dysfunction of 
the metabolic pathways by the chronic 
hyperglycemia. It is postulated that this 
hyperglycemia leads in the reduced ability of tissues 
to detoxify free radicals. This oxidative stress can in 
turn lead to peripheral neuropathy. (2) The polyol 
pathway was found to be a major determinant of this 
oxidative stress. Data suggest that the increase in the 
influx of the substrate in this pathway is the primary 
pathogenic factor in diabetic neuropathy. (3) 
Studies have demonstrated that reduced nerve 
perfusion and hypoxia of endoneurium has also 
played a pivotal role in development of diabetic 
neuropathy. Biopsy was taken from patients suffering 
from mild to moderate neuropathy and it showed 
features like basement membrane thickening, pericyte 
degeneration and endothelial cell hyperplasia. (4, 5) 
Materials and Methods: 
This prospective cross-sectional study was conducted 
at Department of General Medicine, Nishtar Hospital 
Multan, Pakistan from 1st December 2018 to 10th 
March 2019. Patients with both type 1 and 2 diabetes 
were included. Hypertension was defined as having 
blood pressure more than 140/90 mm Hg. A fasting 
cholesterol level of more than 200mg/dl was labelled as 
hypercholesterolemia. 104 consecutive patients 
presenting in outdoor department, fulfilling the 
inclusion criteria were included in the study. Informed 
consent was taken from all patients.  A positive urine 
dipstick was considered as overt diabetic nephropathy 
in the absence of any other causes of proteinuria. 
Serum urea and creatinine were checked for any renal 
disorder. All the patients included in this research had 
their random blood sugar level monitored using an On 
Call® EZ II glucometer. Patients had their HbA1c 
(glycosylated hemoglobin) measured using 
immunoturbidimetric by hospital’s inhouse Laboratory. 
All the patients coming to the OPD had their 
assessment of palpation of dorsalis pedis and posterior 
tibial arteries was made, and they were characterized as 
being “present” or “absent”. The diabetic neuropathy in 
these patients was assessed using the PainDETECT 
questionnaire for the neuropathic pain along with the 
physical examination that was scored using the MNSI 
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Significance: 
Diabetic neuropathy is a very common condition 
prevalent is Diabetics. Neuropathy is present in most 
of the patients affected by diabetes and is major 
cause of their morbidity. The pathogenesis of 
diabetic neuropathy has been attributed to 
dysfunction of metabolic pathways by chronic 
hyperglycemia. This hyperglycemia leads in reduced 
ability of tissues to detoxify free radicals. Current 
study found efficiencies of diabetic neuropathy 
diagnosis techniques. 
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criteria and the neurothesiometer by health care 
professional. 
PainDETECT is an easy questionnaire that is designed 
to differentiate the nociceptive and the neuropathic 
pain. It is designed so the results solely rely on the 
characteristic clinical neuropathic pain. Each parameter 
is graded as to obtain an overall idea of the extent of 
the neuropathy. Michigan neuropathy screening 
instrument (MNSI) was used for screening on basis of 
physical examination. (6) On physical assessment the 
first step was to observe if the appearance of the feet 
was normal. A keen observation was made regarding 
any deformity, callus, infection, fissure or any other 
anomaly that may compel as to label the appearance as 
abnormal.  0 was the score assigned to the normal feet 
and if there was anything that did not fit the norm the 
score was 1 (for each foot). If there was no ulceration, 
the score was 0 but a score of 1 was assigned for an 
ulcer found on each foot. A reflex hammer was used to 
access the ankle reflex. Normal ankle reflex was given 
0 score, diminished reflex 0.5 and 1 was allotted to an 
absent ankle reflex. MNSI also requires the perception 
of vibration to be evaluated. In our study, we used a 
128 Hz vibration tuning fork to aid in our cause. 
Tuning fork was placed at the ball of the big toe. If the 
patient could perceive it then medial malleolus was 
tested. A better perception of vibration sense in the 
medial malleolus was given 0.5 score. If the perception 
was equal in both, the vibration sense was ascertained 
to be normal and given the score 0. Failure to perceive 
vibration sense in big toe was given a score of 1 in each 
foot. To test the presence of pressure sensation in the 
sole of the foot 10g monofilaments (also called as 
Semmes Weinstein monofilaments) were used. The 
heads of 1st, 3rd, 5th metatarsal heads and plantar 
surface of distal hallux. The technique for testing is that 
the patient should have his/her eyes closed and the 
monofilament should be applied to the designated sites 
until it buckles. The buckling shows that a pressure of 
10g has been applied. In this research, disposable 
monofilaments by Booth and Young were used. 
The vibration perception threshold can be semi-
quantitatively assessed using a neurothesiometer. It can 
be assessed by asking the patient to lie down on a 
couch. The stylus of the instrument is then placed over 
the pulp of the hallux. The amplitude of the vibration is 
increased until the patient can perceive the vibration. 
The resultant value obtained is called as the VPT 
(vibration perception threshold). Initially the process is 
done over the proximal site and then the readings are 
repeated over different points of pain on the sole of the 
foot. The results are variable for different 
neurothesiometers used. The one used in our research 
had a normal threshold at 1-10 volts. Anything between 
11-15 was deemed as mild neuropathy. 16-20 volts 
depicted a moderate one and anything above 20 was 
said to be severe neuropathy. A severe neuropathy has 
been strongly associated with the development of 
subsequent foot ulceration. The data was analyzed 
using SPSS-20. 
Results 
HbA1C levels of the patients in this research varied 
from 7-14% with an average of 9.1%. While assessing 
the effectiveness of various methods for diabetic 
neuropathy, three variables were primarily put into use. 
The duration for which the patients had diabetes, the 
type of diabetes they were having and the treatment 
they were currently upon (Table 1). 
MNSI suggests that score of ≥2.5 is considered the 
standard for diabetic neuropathy. Twenty-nine of the 
patients in the research were suffering from diabetic 
neuropathy according to the criteria of MNSI. Most of 
the patients in this category had comorbidity as well. 
Nine of the patients were hyperlipidemic with 8 taking 
medications for it. 11 were hypertensive and had a 
reduced renal function and 13 had some degree of 
diabetic retinopathy (Table 2). 
The PainDETECT questionnaire helped us in 
identifying whether the pain, that the patients in our 
research had was of nociceptive or neuropathic in 
origin. Forty-two of the patients were screened as 
having neuropathic pain. Twenty-four had them labeled 
as nociceptive while the result was unclear in about 38 
of the patients (Fig. 1). 
A score of greater than 18 (19-38) is considered as 
neuropathic pain. The average duration of diabetes for 
individuals in this group was 13 years. Of the 42 
patients who were screened to have a neuropathic pain, 
21 of them were hypertensive with 16 taking regular 
medications for it. 4 were hyperlipidemic and 17 had 
some degree of retinopathy (Table 3). 
Among the 104 patients in our research, 79 had some 
sort of neuropathy. Only 26 had the vibration threshold 
below 10 volts. 32 had mild neuropathy, 26 had 
moderate while 20 patients suffered from severe 
neuropathy. Of the 29 patients deemed neuropathic 
using the MNSI 27 were also labeled as neuropathic 
using neurothesiometer. Similarly, all the 40 
neuropathic pain cases in the PainDETECT group were 
also tested positive on neurothesiometer (Table 4). 
The results from neurothesiometer not only covered 
majority of the individuals who had co morbidities but 
there were a good number of individuals who were 
asymptomatic but had an increased vibration 
perception threshold (Fig. 2). 
Int J Front SciVolume 4 (Issue 1) Original Article 
  
 
4 
 
Diagnosing Diabetic Neuropathy 
 
Table 1: Demographic information of the patients 
(n=104) 
Age 53.92±13.158 
Male/Female 42/62 
DM disease length (years) 10.45±6.753 
Type 1/ Type 2 24/80 
BMI (kg/m2 ) 32.6 
Patients on oral hypoglycemic 22 
Patients taking insulin only 31 
Patients taking both regimens 51 
 
Table 2: Number of positive patients (n=29) 
Mean score of total subjects  1.6058±1.14203 
Mean duration of DM 
(years) 
18.69±5.373 
Type 1/ Type 2 7/22 
Oral hypoglycemic only 4 
Insulin only 6 
Oral hypoglycemic and 
insulin 
19 
 
Table 3: Neurologic pain (n=42) 
Mean score 17.1±6.9 
Mean duration of diabetes 15.14±6.580 
Type 1/ Type 2 5/37 
Oral hypoglycemics only 8 
Insulin only 8 
Oral hypoglycemics and 
Insulin 
26 
 
Table 4: Number of neuropathic patients (n=79) 
Mean duration (years) 11.67±6.978 
Type 1/Type 2 13/65 
Oral hypoglycemic only 14 
Insulin only 20 
Oral hypoglycemics and 
insulin 
44 
 
 
Fig. 1: PainDETECT screening 
 
 
Fig. 2: Comparison of neuropathic assessment 
 
Discussion 
Diabetic neuropathy refers to a broad term 
encompassing both the peripheral and the autonomic 
neuropathies. Among the peripheral neuropathies, 
distal symmetric neuropathy is the most common 
form. Association of neuropathy with glycemic control 
and duration has been well established by multiple 
studies (1, 7) emphasizing the importance of early 
detection and strict glycemic control. There are 
documented suggestions that in case of type 1 
diabetes, glycemic control has been fundamental in 
controlling/prolonging the neuropathy free interval as 
opposed to type 2 diabetes that not only requires tight 
glycemic control but the lipid profile, lifestyle habits 
and blood pressure all have a vital role to play. (8) 
There is evidence of obesity and hypertriglyceridemia 
being individual factors in the early onset of 
neuropathy, independent from tight glycemic control. 
(9) When considering the possibility of diabetic 
neuropathy, vascular risk factors have their own 
specific role to play as evident by the EURODIAB 
prospective complications study. (10) 
In our study, we evaluated 104 patients, suffering from 
both type 1 and type 2 diabetes. The focus, however, 
was their development of neuropathy. Being a 
debilitating result of diabetes, it is crucial that there 
should be a system for early detection of neuropathy. 
Here we employed three different methods, MNSI, 
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PainDETECT and neurothesiometer, in order to assess 
their efficiency in detecting neuropathy in diabetic 
patients. 
MNSI has been used as a screening tool for diabetic 
neuropathy. It includes two components, a 15-item 
questionnaire and a physical examination involving 
lower limb. MNSI has been regarded as an easily 
workable and elementary screening tool to be used in 
clinical examination for diagnosis of diabetic 
neuropathy. (11) MNSI score was ≥2.5 in 29 cases 
labelling them as neuropathic. In a study in Turkey, 
they assessed patients on the number of questions they 
answered on the MNSI questionnaire. (6) They 
employed a total of 106 patients and 34 of them had 
positive history regarding neuropathy. 24 of their 
patients gave a positive response for ≥7 questions and 
among 72 not diagnosed with diabetic neuropathy, 28 
had a positive response for ≥7 questions. This brings 
us to our research. Of the 29 who were having a ≥2.5 
score on the MNSI 22 gave an affirmative answer to 
≥7 questions. Of the remaining having a reduced score 
on MNSI, there were 21 cases where the answer was 
same implying that diagnosing neuropathy based on 
symptoms can be evasive. 
Screening questionnaires like PainDETECT are 
convenient to use in daily practice but a study 
conducted implies that the major characteristics in this 
questionnaire, like numbness and burning sensations, 
are subjective and so therefore it is not sufficient to 
point out the numerous sensory loses attributed to 
neuropathy. (12) This questionnaire has though 
afforded the benefit of segregating patients based on 
nociceptive and neuropathic pain and at the same time 
helped clinicians to identify if a particular patient is to 
be referred to a specialist for pain management. An 
extensive study has shown PD-Q being used for 
chronic pain and it is being assumed that in the future 
it can be employed to partition the individual sensory 
profiles aiding the medical personnel to personify the 
pain treatment. (13) Another important benefit of this 
questionnaire is that it does not require any sort of 
clinical examination and anyone, even the patient 
themselves, can grade them. This will help them 
understand as to when they need professional help. 
Vibration sense is one of the earliest ones to be lost 
when the diabetic neuropathy sets in. This along with 
pain and numbness start distally in fingers and toes 
and then extending proximally producing the classic 
‘Glove and Stocking’ deformity. In our research we 
used a portable neurothesiometer, that was easy to use 
and had a lower threshold than tuning forks to 
determine the vibration sense in patients. VPT 
determined by neurothesiometer labeled 78 patients in 
our research as suffering from diabetic neuropathy that 
was almost twice what the other methods had detected. 
A study has shown that VPT determined with 
neurothesiometer is relatively constant facilitating us 
to use this as a tool in clinical trials. (14, 15) A 
possibility is that the neurothesiometer may have over 
predicted the number of neuropathic patients. We 
compared the ones who were ‘mildly’ suffering from 
the disease according to the neurothesiometer. Of the 
32 people in this category, only 1 was diagnosed as 
having neuropathy by MNSI while PainDETECT had 
4 in the unclear category with only 2 as neuropathic. 
Moreover, neurothesiometer also had an edge as it 
detected a few of those patients to be neuropathic who 
had no other comorbidities making it a useful clinical 
tool in early screening of Diabetic neuropathy. 
Conclusion 
Neurothesiometer is far superior than other two 
methods in diagnosing early neuropathy and 
preventing its complications. 
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